General Western Blot Reagents
Abcam 3-Cyano-7-etho x ycoumarin, Fluorogenic cytochrome P450 monoo x ygenase substrate, 100MG
MW 215.2 g/mol, Purity >99%. Fluoreogenic cytochrome P450 mixed-function monooxygenase substrate. Metabolized to the fluorescent compound 3-cyano-7-hydroxycoumarin. About 50-100 times more sensitive than conventional substrate ethoxy-resorufin due to higher turn over rate.
The product is subject to the following: Abcam Restricted Use Statement
Abcam N-He x anoyl-L-homoserine lactone, involved in quorum sensing, 10MG
MW 199.3 g/mol, Purity >98%. Autoinducer involved in quorum sensing. Member of N-acyl-homoserine lactone (AHL) family that regulate gene expression in gram-negative bacteria and are involved in the processes of bacterial quorum sensing.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A-967079, TRPA1 receptor antagonist, 50MG
MW 207.24 Da, Purity >98%. Potent and selective TRPA1 receptor antagonist (IC₅₀ = 67 nM). Displays no activity at other TRP channels. Analgesic agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Concanamycin C, H+-ATPase inhibitor, 500UG
MW 823.1 Da, Purity >98%. Potent, selective vacuolar-type H+-ATPase inhibitor. Macrolide antibiotic agent. Concanamycin A (ab144227) analog. Shows antiproliferative and potent antifungal effects.
The product is subject to the following: Abcam Restricted Use Statement
Abcam DCIA, Fluorescent thiol-reactive neutral probe, 100MG
MW 490.33 g/mol, Purity >85%. Fluorescent thiol-reactive neutral probe. Self-quenching until it reacts with thiol groups and regains its strong fluorescence.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BD 1008 dihydrobromide, delta1-receptor antagonist, 50MG
MW 463.1 Da, Purity >96%. Potent and selective δ1-receptor antagonist (Ki = 0.34 nM). Therapeutic agent. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Manumycin A, Ras farnesyltransferase inhibitor, 5MG
MW 550.6 Da, Purity >96%. Potent, selective, competitive cell-permeable Ras farnesyltransferase (Ki = 1.2 μM) inhibitor. IκB kinase inhibitor. Antibiotic agent. Induces apoptosis. Shows antitumor effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam gamma-Tocotrienol, Form of vitamin E, 5MG
MW 410.6 Da, Purity >98%. Form of vitamin E. Antioxidant agent. Tocotrienol α (ab144451), β (ab145176) and δ (ab144449) analog. Induces apoptosis in cancer cells. Shows antitumor and antihypertensive effects in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Cysteamine hydrochloride, Degradation product of cystine, 100G
MW 113.61 Da, Purity >98%. Degradation product of cystine. Various pharmacological activities. Effective against cystinosis. Antitumor agent. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Rp-8-Br-cGMPS, cGMP blocker, 500UG
MW 462.15 Da, Purity >98%. cGMP blocker. Competitively inhibits relaxation elicited by 8-Br-cGMP in isolated rabbit aorta contracted by phenylephrine at 30 μM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Quinol 2, Antitumor agent, 5MG
MW 243.28 Da, Purity >99%. Selective antitumor agent. Active against colon, renal and breast carcinomas in vitro and ex vivo. Inhibits thioredoxin reductase with potencies correlated with antiproliferative and cytotoxic effects. Potent inhibitory effect in NCI 60 cells (GI₅₀ =0.23 μM and LC₅₀ = 3.39 μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Gramicidin A, Antibiotic agent, 5MG
MW 1882.3 Da, Purity >90%. Gramicidin A, Antibiotic agent. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (R)-Butaprost, EP2 agonist, 10MG
MW 408.6 Da, Purity >98%. Selective EP2 agonist. PGE2 structural analog. Inhibits chemotaxis (EC50 = 106 nM, maximal effect of PGE2). Increases neutrophil cyclic AMP levels.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BATCP, HDAC6 substrate, 2MG
MW 499.5 Da, Purity >99%. Selective HDAC6 substrate. Active in vitro. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ABD-F, Fluorogenic reagent for thiol labeling, 10MG
MW 217.18 g/mol, Purity >98%. Highly reactive, sensitive fluorogenic reagent for thiol labelling. Selectively labels protein cysteine residues without side chain modification or N-terminal blockage. It has a benzofurazan moiety that produces a highly fluorescent compound through the reaction with a sulfhydryl group.
The product is subject to the following: Abcam Restricted Use Statement